Amgen Lifted, Vistra Cut as Analysts Reshuffle

Amgen dominated Wednesday's analyst tape. Three separate firms raised their price targets on the biotech giant within hours. RBC Capital moved to $470 from $430. Wells Fargo went to $460 from $430. Truist lifted its own to $398 from $380. All three kept Hold or Buy ratings. Amgen's market cap sits at $249B, with short interest a modest 2.4% of free float.

The sharpest single call was Guggenheim's fresh Buy initiation on Lockheed Martin with a $735 target. The defence firm carries a $148B market cap. Analyst Michael Ciarmoli at Guggenheim set no prior target, making this a clean new bullish opening.

The day's clearest downgrade hit Vistra Corp. Keybanc analyst Sophie Karp cut the power generator from Buy to Hold. No target price was given. At $47B market cap, Vistra has been a high-momentum energy name. Short interest stands at 3.3% of free float.

Advanced Micro Devices drew split opinions. Truist's William Stein raised his target to $605 from $594. RBC's Srini Pajjuri kept a Hold with no target change at $540. The divergence reflects ongoing uncertainty around AMD's AI chip trajectory.

Truist also nudged up targets on Arista Networks, AMETEK, and Diamondback Energy, all with Buy ratings intact. Logistics firm Expeditors International got a target lift to $200 from $175, though Truist kept a Hold.